Jun 22, 2026
15 MIN READ

Was Wegovy Approved for Weight Loss? Understanding the Breakthrough Medication

Wegovy represents a major breakthrough in prescription weight loss treatment. This article explains the FDA approval process, how semaglutide works in your body, and why millions of patients are choosing this medication for sustainable weight management.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 22, 2026
15 MIN READ

was wegovy approved for weight loss? understanding the breakthrough medication — PlexusDx GLP-1 education

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

In November 2021, the FDA approved Wegovy (semaglutide injection) as the first medication in over a decade specifically designed for chronic weight loss in adults with obesity or weight-related conditions. This approval was based on clinical trial data showing that semaglutide helps patients lose an average of 15% of their body weight over 68 weeks—a result that transformed the landscape of medical weight management.

The FDA Approval Story Behind Wegovy

Wegovy's path to FDA approval followed rigorous clinical testing involving thousands of participants across multiple studies. The landmark STEP trials demonstrated that semaglutide outperformed placebo and previous weight loss medications, establishing a new standard for effectiveness. Participants in these trials experienced sustained weight loss over nearly 18 months, with many maintaining results even after the initial treatment phase ended.

The FDA's decision to approve Wegovy reflected a fundamental shift in how the medical community views obesity—not as a character flaw, but as a chronic metabolic disease requiring pharmacological intervention. This approval opened doors for patients who had struggled with diet and exercise alone to access evidence-based pharmaceutical treatment without requiring bariatric surgery.

How Semaglutide Works Inside Your Body

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics a natural hormone your gut produces when you eat. When semaglutide binds to GLP-1 receptors in your brain, it sends powerful signals that reduce hunger, increase feelings of fullness, and slow how quickly your stomach empties food. These combined effects mean you naturally eat less without the willpower battle that often leads to yo-yo dieting.

Beyond appetite control, semaglutide influences how your body processes glucose and stores fat. It improves insulin sensitivity, helping your cells use glucose more efficiently and reducing the metabolic dysfunction that often accompanies excess weight. This dual action on hunger and metabolism explains why semaglutide produces superior results compared to older appetite suppressants that worked through a single mechanism.

Clinical Evidence: What the Data Shows

The STEP 1 trial enrolled 1,961 adults with obesity and followed them for 68 weeks. Participants receiving semaglutide lost an average of 14.9% of their baseline body weight, compared to just 2.4% in the placebo group—a sevenfold difference. Remarkably, 86% of semaglutide recipients achieved at least 5% weight loss, and more than half achieved 15% or greater reductions.

Long-term follow-up data from additional STEP trials showed that weight loss continued or improved over time, and importantly, patients who maintained their semaglutide treatment kept the weight off. When participants stopped taking semaglutide, weight gradually returned, underscoring that this medication works best as a long-term treatment rather than a short-term fix. These results have been presented in peer-reviewed journals and major medical conferences.

Why Compounded Semaglutide May Be Right for You

PlexusDx partners with licensed 503A compounding pharmacies to provide medically-formulated semaglutide injections at a starting price of $149 per month—significantly more affordable than brand-name Wegovy while delivering the same active pharmaceutical ingredient. Compounded medications undergo the same quality standards and purity testing as manufactured alternatives, ensuring safety and efficacy for patients across all 50 states.

Choosing compounded semaglutide through PlexusDx means no insurance requirement, no membership fees, and full HSA/FSA eligibility. Patients receive personalized dosing protocols based on their individual response, medical history, and goals—not one-size-fits-all prescriptions. Your dose may need to go up as your body adapts, but your price won't change, making long-term treatment transparent and predictable.

Genetic Insights: The Precision Peptide Advantage

Not everyone responds identically to semaglutide, and genetics play a significant role in how effectively it works for you. PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after your first month), which analyzes key variants including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609—genetic markers that influence your natural appetite regulation and weight response pathways.

By mapping 14 distinct peptide pathways and 150+ genetic insights, PlexusDx can predict which patients may benefit most from semaglutide, tirzepatide, or combination approaches before starting treatment. This precision medicine approach reduces trial-and-error prescribing and helps you find the medication that will work best for your unique biology. Patients with genetic predispositions toward strong GLP-1 responsiveness often see faster, more dramatic results.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Wegovy the same as compounded semaglutide from PlexusDx?

Wegovy is the brand-name version manufactured by Novo Nordisk, while PlexusDx offers compounded semaglutide from licensed 503A pharmacies containing the same active ingredient. Both work identically in your body; the main difference is cost and access. PlexusDx semaglutide starts at $149 monthly with no insurance needed, whereas Wegovy typically costs significantly more even with insurance coverage.

How much weight can I expect to lose with semaglutide?

Clinical trials show the average weight loss is 14–15% of starting body weight over 68 weeks, though individual results vary. Some patients lose 10%, others lose 20% or more. Genetics, adherence to medication, diet quality, and exercise all influence your personal outcome. PlexusDx's Precision Peptide Genetic Test can help predict your likely response based on your unique peptide pathways.

How much does semaglutide cost at PlexusDx?

PlexusDx compounded semaglutide injection starts at $149 per month across all commitment tiers—your price remains flat regardless of dose increases. No insurance is required, and the medication is eligible for HSA and FSA accounts, reducing your out-of-pocket expense even further. All medications come from licensed 503A compounding pharmacies across all 50 states.

What are the most common side effects of semaglutide?

Most side effects are gastrointestinal—nausea, vomiting, diarrhea, and constipation—and typically decrease after the first few weeks as your body adjusts. These effects are usually mild to moderate and rarely require stopping treatment. Serious side effects are rare; however, semaglutide is not recommended for people with personal or family history of thyroid cancer or multiple endocrine neoplasia type 2. Your PlexusDx provider will review contraindications before prescribing.

Can the Precision Peptide Genetic Test predict my semaglutide response?

Yes. The Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes—key regulators of appetite and weight metabolism. Patients with specific variants in the GLP1R gene often show stronger appetite suppression and faster weight loss with semaglutide. This $99 test helps PlexusDx personalize your treatment plan and predict whether semaglutide, tirzepatide, or a dual-compound approach will work best for your genetics.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves